SARS-CoV-2-specific virulence factors in COVID-19.
COVID-19
SARS-CoV-2
host immune response
interferon
virulence factors
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
14
09
2020
revised:
14
10
2020
accepted:
19
10
2020
pubmed:
22
10
2020
medline:
3
3
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
The paucity of knowledge about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific virulence factors has greatly hampered the therapeutic management of patients with coronavirus disease 2019 (COVID-19). Recently, a cluster of studies appeared, which presented empirical evidence for SARS-CoV-2-specific virulence factors that can explain key elements of COVID-19 pathology. These studies unravel multiple structural and nonstructural specifics of SARS-CoV-2, such as a unique FURIN cleavage site, papain-like protease (SCoV2-PLpro), ORF3b and nonstructural proteins, and dynamic conformational changes in the structure of spike protein during host cell fusion, which give it an edge in infectivity and virulence over previous coronaviruses causing pandemics. Investigators provided robust evidence that SARS-CoV-2-specific virulence factors may have an impact on viral infectivity and transmissibility and disease severity as well as the development of immunity against the infection, including response to the vaccines. In this article, we are presenting a summarized account of the newly reported studies.
Substances chimiques
Spike Glycoprotein, Coronavirus
0
Virulence Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1343-1350Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271-280. https://doi.org/10.1016/j.cell.2020.02.052
Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med Published online April 23 2020:1-7. https://doi.org/10.1038/s41591-020-0868-6
Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742. https://doi.org/10.1016/j.antiviral.2020.104742
Naqvi AAT, Fatima K, Mohammad T, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165878. https://doi.org/10.1016/j.bbadis.2020.165878
Xu J, Zhao S, Teng T, et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses 2020;12(2):244. https://doi.org/10.3390/v12020244
Johnson BA, Xie X, Kalveram B, et al. Furin cleavage site is key to SARS-CoV-2 pathogenesis. bioRxiv Prepr Serv Biol. Published online August 26 2020. https://doi.org/10.1101/2020.08.26.268854
Xia S, Lan Q, Su S, et al. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct Target Ther. 2020;5(1):1-3. https://doi.org/10.1038/s41392-020-0184-0
Jaimes JA, Millet JK, Whittaker GR. Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site. iScience. 2020;23(6):101212. https://doi.org/10.1016/j.isci.2020.101212
Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25-32. https://doi.org/10.1016/j.cytogfr.2020.05.003
Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020;584(7821):463-469. https://doi.org/10.1038/s41586-020-2588-y
Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014;59(1-3):118-128. https://doi.org/10.1007/s12026-014-8534-z
Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827. https://doi.org/10.3389/fimmu.2020.00827
Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature Published online May 20 2020:1-7. https://doi.org/10.1038/s41586-020-2355-0
Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev Published online April 25 2020;53:38-42. https://doi.org/10.1016/j.cytogfr.2020.04.002
Zhang Y, Li J, Zhan Y, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004;72(8):4410-4415. https://doi.org/10.1128/IAI.72.8.4410-4415.2004
Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016;38(4):471-482. https://doi.org/10.1007/s00281-016-0558-0
Channappanavar R, Fehr AR, Zheng J, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;129(9):3625-3639. https://doi.org/10.1172/JCI126363
Frieman M, Baric R. Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation. Microbiol Mol Biol Rev. 2008;72(4):672-685. https://doi.org/10.1128/mmbr.00015-08
Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020;181(5):1036-1045. https://doi.org/10.1016/j.cell.2020.04.026
Konno Y, Kimura I, Uriu K, et al. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant. Cell Rep. 2020;32(12):108185. https://doi.org/10.1016/j.celrep.2020.108185
Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020;369(6504):718-724. https://doi.org/10.1126/science.abc6027
Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med Published online June 18 2020:1-5. https://doi.org/10.1038/s41591-020-0965-6
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. N Engl J Med. 2020;383(11):1085-1087. https://doi.org/10.1056/NEJMc2025179
Liu A, Wang W, Zhao X, et al. Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery. Clin Microbiol Infect Published online July 2020. https://doi.org/10.1016/j.cmi.2020.07.009
Kaneko N, Kuo H-H, Boucau J, et al. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell 2020;183(1):143-157.https://doi.org/10.1016/j.cell.2020.08.025
Chen Yongwen, Feng Z, Diao B, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes [published online ahead of print March 31, 2020]. medRxiv. https://doi.org/10.1101/2020.03.27.20045427
Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012;30(1):429-457. https://doi.org/10.1146/annurev-immunol-020711-075032
Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10:766-788. https://doi.org/10.1016/j.apsb.2020.02.008
Shin D, Mukherjee R, Grewe D, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 2020:1-10. https://doi.org/10.1038/s41586-020-2601-5
Shanker AK, Bhanu D, Alluri A, Gupta S. Whole-genome sequence analysis and homology modelling of the main protease and non-structural protein 3 of SARS-CoV-2 reveal an aza-peptide and a lead inhibitor with possible antiviral properties. New J Chem. 2020;44(22):9202-9212. https://doi.org/10.1039/d0nj00974a
Rut W, Lv Z, Zmudzinski M, et al. Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design. bioRxiv Prepr Serv Biol. Published online 2020. https://doi.org/10.1101/2020.04.29.068890
Cai Y, Zhang J, Xiao T, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science 2020;369(6511):1586-1592. https://doi.org/10.1126/science.abd4251
Goetz L, Yang J, Greene W, Zhu Y. A COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies. J Appl Lab Med. Published online August 3 2020. https://doi.org/10.1093/jalm/jfaa137
Wu F, Liu M, Wang A, et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020;180(10):1356-1362. https://doi.org/10.1001/jamainternmed.2020.4616
van der Heide V. Neutralizing antibody response in mild COVID-19. Nat Rev Immunol. 2020;20(6):352. https://doi.org/10.1038/s41577-020-0325-2
Thoms M, Buschauer R, Ameismeier M, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science 2020;369(6508):1249-1255.
Viswanathan T, Arya S, Chan S-H, et al. Structural basis of RNA cap modification by SARS-CoV-2. Nat Commun. 2020;11(1):3718. https://doi.org/10.1038/s41467-020-17496-8
Anand P, Puranik A, Aravamudan M, Venkatakrishnan AJ, Soundararajan V. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. eLife 2020;9. https://doi.org/10.7554/eLife.58603
Mutchler SM, Kleyman TR. New insights regarding epithelial Na+ channel regulation and its role in the kidney, immune system and vasculature. Curr Opin Nephrol Hypertens. 2019;28(2):113-119. https://doi.org/10.1097/MNH.0000000000000479
Wyne BM, Zou L, Linck V, Hoover RS, Ma HP, Eaton DC. Regulation of lung epithelial sodium channels by cytokines and chemokines. Front Immunol. 2017;8(Jul). https://doi.org/10.3389/fimmu.2017.00766
Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLOS One. 2020;15(5):e0233147. https://doi.org/10.1371/journal.pone.0233147
Xu H, Ferro TJ, Chu S. Cigarette smoke condensate inhibits ENaC α-subunit expression in lung epithelial cells. Eur Respir J. 2007;30(4):633-642. https://doi.org/10.1183/09031936.00014107
Li Y, Chang J, Cui Y, et al. Novel mechanisms for crotonaldehyde-induced lung edema. Oncotarget 2017;8(48):83509-83522. https://doi.org/10.18632/oncotarget.17840
Bouhaddou M, Memon D, Meyer B, et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell 2020;182(3):685-712.https://doi.org/10.1016/j.cell.2020.06.034
Klann K, Bojkova D, Tascher G, Ciesek S, Münch C, Cinatl J. Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication. Mol Cell. 2020;80:164-174. https://doi.org/10.1016/j.molcel.2020.08.006
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70. https://doi.org/10.1016/S0092-8674(00)81683-9
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708-1720. https://doi.org/10.1056/NEJMoa2002032
Yelin D, Wirtheim E, Vetter P, et al. Long-term consequences of COVID-19: research needs. Lancet Infect Dis. 2020;20(10):1115-1117. https://doi.org/10.1016/S1473-3099(20)30701-5
Rubino F, Amiel SA, Zimmet P, et al. New-onset diabetes in COVID-19. N Engl J Med. 2020;383(8):789-790. https://doi.org/10.1056/NEJMc2018688
Abobaker A, Raba AA. Does COVID-19 affect male fertility? World J Urol. 2020:1-2. https://doi.org/10.1007/s00345-020-03208-w